ArticleProbiotics and antimicrobial proteins2026
Screening and Genetic Analysis of Bifidobacterium longum subsp. Longum dipro-X for IBD Alleviation.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elucidation ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Given the limitations of current IBD treatments, this study conducted an in-depth investigation of 17 human-derived Bifidobacterium longum subsp. longum strains. Primary screening using a lipopolysaccharide (LPS)-induced RAW264.7 macrophage inflammation model identified strain F05-044-CM-09 as exhibiting significantly stronger inhibition of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) production compared to other strains. To explore the genetic basis of its anti-inflammatory effect, strain-specific gene analysis revealed that F05-044-CM-09 harbors a gene encoding the CHAP domain, suggesting that anti-inflammatory efficacy may involve immunomodulation through dendritic cell activation and interleukin-2 (IL-2) production. A safety assessment performed prior to animal experiments confirmed the absence of virulence genes and genes encoding D-lactate production. In a dextran sulfate sodium (DSS)-induced murine colitis model, F05-044-CM-09 intervention significantly ameliorated disease phenotypes by mitigating body weight loss and colon shortening, restoring colonic gland architecture, and reducing inflammatory cell infiltration. Analysis of serum biomarkers showed that F05-044-CM-09 significantly reduced LPS levels, whereas serum TNF-α levels showed a decreasing trend that was not statistically significant. However, colonic TNF-α concentrations were significantly reduced following F05-044-CM-09 intervention. In summary, F05-044-CM-09 has the potential to alleviate enteritis and a good safety profile. It is a promising candidate for the development of anti-inflammatory probiotics and offers new possibilities for IBD treatment.
Indexed as
Identifiers
41060597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.